Trial Profile
BAY59-7939, Japanese Phase II in Atrial Fibrillation Trial Status.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Deep vein thrombosis; Embolism; Pulmonary embolism; Stroke
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors Bayer
- 06 Nov 2008 New trial record.